Ensuring people have access to insulin and diabetes care is essential, especially during emergencies and in humanitarian settings where diabetes care is even more limited.

Learn more ⬇️
msfaccess.org/what-it-mean...

In 2024, pharmaceutical corporation Novo Nordisk decided to stop producing human insulin pens (which Lecritia uses).

Although Novo committed to supply South Africa with another type of insulin pen – analogues – they are priced very high and may not result in equitable access.

Lecritia, from South Africa, is comfortable using insulin pens.

She reacted to possibly switching back to less convenient vials & syringes due to a decision by Novo Nordisk to discontinue human insulin pens (recorded in 2024).

"Antibiogo was developed in collaboration with the people and countries that need it."

We spoke on Antibiogo last week at the World Health Summit, sharing how it was developed by, for, and with the countries where we work.

www.youtube.com/watch?v=Oq6A...
#Innovation #WHS2025

In the past 3 years, Poland has taken steps to improve TB treatment access by aligning national policies with WHO recommendations. But, many EU & EEA countries have not updated their guidelines and continue to grapple with barriers in accessing effective medicines and treatment.

Olga*, a person living with DR-TB in Warsaw, was started on the all-oral, six-month DR-TB regimen as recommended by the WHO to replace the previous DR-TB treatment regimen which was less effective and more toxic.

Governments must agree on the most ambitious and concretely actionable political declaration to ensure access to insulin and diabetes care to all who need it, including during emergencies and in humanitarian settings.

msfaccess.org/what-it-mean...

More than 800 million people have diabetes, the majority of whom live in low- and middle-income countries.

For people with type 1 diabetes, insulin is lifesaving, but it is often unavailable in low-resource and emergency settings, and unaffordable elsewhere.